New hope for kids with rare cancers: alectinib trial launches
NCT ID NCT04774718
First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 6 times
Summary
This study tests the drug alectinib in children and teens with ALK fusion-positive solid or central nervous system (CNS) tumors that have not responded to other treatments or have no standard therapy. The goal is to see if alectinib is safe and can shrink or control these tumors. About 42 participants will take alectinib capsules twice daily in 28-day cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- alectinib
- What this could lead to
- If it works, this could provide a new treatment option for children with these rare, hard-to-treat tumors.
- What could go wrong
- This is an early-phase trial with only 42 participants, so results may not apply to all patients. Side effects are possible, and the drug may not shrink tumors in everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALK FUSION-POSITIVE SOLID OR CNS TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
Beijing Children's Hospital, Capital Medical University
Beijing, 100045, China
-
CHU Sainte-Justine
Montreal, Quebec, H3T 1C5, Canada
-
Centre Léon Bérard, Institut d?Hémato-Oncologie Pédiatrique
Lyon, 69373, France
-
Children's Minnesota
Minneapolis, Minnesota, 55404, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Dipartimento di Scienze Pediatriche Adolescenza
Turin, Piedmont, 10126, Italy
-
Graacc-Grupo de Apoio ao adolescente e a crianca com cancer
São Paulo, São Paulo, 04038-030, Brazil
-
Great North Children's Hospital
Newcastle upon Tyne, NE1 4LP, United Kingdom
-
Great Ormond Street Hospital
London, WC1N 3JH, United Kingdom
-
Hospital Infantil Universitario Nino Jesus
Madrid, 28009, Spain
-
Hospital Universitari i Politecnic La Fe
Valencia, 46026, Spain
-
Hospital Universitario Virgen del Rocio
Seville, 41 41013, Spain
-
Hospital de Cancer de Barretos
Barretos, São Paulo, 14784-400, Brazil
-
Hôpital de la Timone, Oncologie Pédiatrique
Marseille, 13385, France
-
Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris
Paris, 75248, France
-
Istituto Giannina Gaslini-Ospedale Pediatrico IRCCS
Genoa, Liguria, 16147, Italy
-
Istituto Nazionale Tumori di Milano
Milan, Lombardy, 20133, Italy
-
Johns Hopkins All Children's Hospital
St. Petersburg, Florida, 33701, United States
-
Lucile Packard Children's Hospital
Palo Alto, California, 94304, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Rigshospitalet
København Ø, 2100, Denmark
-
Royal Children's Hospital
Parkville, Victoria, 3052, Australia
-
Royal Manchester Childrens Hospital
Manchester, M13 9WL, United Kingdom
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
St. Jude Children'S Research Hospital
Memphis, Tennessee, 38105, United States
-
Sydney Children's Hospital
Randwick, New South Wales, 2031, Australia
-
The Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
-
University of Michigan, C.S. Mott Children's Hospital
Ann Arbor, Michigan, 48109, United States
-
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, 200092, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.